// App-Quantinova.ai

6075 : Neoadjuvant carboplatin, nab-paclitaxel and cetuximab prior to standard of care chemoradiotherapy for N2b or unresectable squamous head and neck cancer.

Researchers

Presenter

  • Jared Weiss

Principal Investigators

  • David N. Hayes

  • Allison Mary Deal

  • Bhishamjit S. Chera

  • Mark Christian Weissler

  • Barbara A. Murphy

  • Jay Justin Liao

  • Juneko E. Grilley-Olson

  • Jill Gilbert

Medical Centers

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Biostatistics Core Facility, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • University of North Carolina, Chapel Hill, NC

  • Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Vanderbilt University Medical Center, Nashville, TN

  • University of Washington, Seattle, WA

  • UNC Chapel Hill, Chapel Hill, NC

  • Vanderbilt University School of Medicine, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Anaphylaxis

  • Solid malignancies

Biomarkers

  • Immunoglobulin E

Drug/Treatment

  • Carboplatin

  • Paclitaxel

  • Erbitux

  • MAb C225

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01412229

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved